Target: Alpha Synuclein
Conjugate: FITC
Product Type: Polyclonal
Immunogen: Recombinant Human alpha Synuclein Fibril
Swiss-Prot: P37840
Purification: Protein A Purified
Storage Buffer: 640.91mM DMSO, 136.36mM Ethanolamine, and 9.09mM Sodium Bicarbonate in 90.9% PBS
Concentration: 1 mg/ml
Specificity: Detects ~14.46kda.
Cellular Localization: Cytoplasm / Membrane / Nucleus / Cell Junction / Synapse / Secreted
Tissue Specificity: Highly expressed in brain (presynaptic nerve terminals) but is also expressed in low concentrations in all tissues examined except in liver.
Scientific Background: Alpha-Synuclein (SNCA) is expressed predominantly in the brain, where it is concentrated in presynaptic nerve terminals (1). Alpha-synuclein is highly expressed in the mitochondria of the olfactory bulb, hippocampus, striatum and thalamus (2). Functionally, it has been shown to significantly interact with tubulin (3), and may serve as a potential microtubule-associated protein. It has also been found to be essential for normal development of the cognitive functions; inactivation may lead to impaired spatial learning and working memory (4). SNCA fibrillar aggregates represent the major non A-beta component of Alzheimers disease amyloid plaque, and a major component of Lewy body inclusions, and Parkinson's disease. Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive accumulation in selected neurons of protein inclusions containing alpha-synuclein and ubiquitin (5, 6).
References: 1. “Genetics Home Reference: SNCA”. US National Library of Medicine. (2013).2. Zhang L., et al. (2008) Brain Res. 1244: 40-52.3. Alim M.A., et al. (2002) J Biol Chem. 277(3): 2112-2117.4. Kokhan V.S., Afanasyeva M.A., Van'kin G. (2012) Behav. Brain. Res. 231(1): 226-230.5. Spillantini M.G., et al. (1997) Nature. 388(6645): 839-840.6. Mezey E., et al. (1998) Nat Med. 4(7): 755-757.
Field of Use: Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
Deutsch
English
